Advertisement

Advertisement

BCAX Stock Latest News

Bicara Therapeutics: Buy Rating Reiterated on FICERA’s Survival Benefit in Difficult HNSCC Segment, Price Target Maintained at $30

RatingsBicara Therapeutics: Buy Rating Reiterated on FICERA’s Survival Benefit in Difficult HNSCC Segment, Price Target Maintained at $30

Bicara Therapeutics Secures Boston Headquarters Through Sublease

PremiumCompany Announcements

Bicara Therapeutics Secures Boston Headquarters Through Sublease

1M ago

Bicara Therapeutics’ Earnings Call Signals Pivotal Progress

PremiumCompany Announcements

Bicara Therapeutics’ Earnings Call Signals Pivotal Progress

1M ago

BMO starts Bicara at Outperform, sees meaningful upside potential

PremiumThe Fly

BMO starts Bicara at Outperform, sees meaningful upside potential

1M ago

Bicara Therapeutics initiated with an Outperform at BMO Capital

PremiumThe Fly

Bicara Therapeutics initiated with an Outperform at BMO Capital

2M ago

Bicara Therapeutics price target lowered to $34 from $35 at BofA

PremiumThe FlyBicara Therapeutics price target lowered to $34 from $35 at BofA

2M ago

Bicara Therapeutics price target raised to $20 from $18 at Goldman Sachs

The Fly

Bicara Therapeutics price target raised to $20 from $18 at Goldman Sachs

2M ago

Bicara Therapeutics price target raised to $39 from $28 at BTIG

The Fly

Bicara Therapeutics price target raised to $39 from $28 at BTIG

2M ago

Bicara Therapeutics price target raised to $20 from $18 at Mizuho

PremiumThe Fly

Bicara Therapeutics price target raised to $20 from $18 at Mizuho

2M ago

Bicara Therapeutics price target raised to $33 from $30 at Wedbush

PremiumThe Fly

Bicara Therapeutics price target raised to $33 from $30 at Wedbush

2M ago

Bicara Therapeutics price target raised to $39 from $37 at Morgan Stanley

PremiumThe Fly

Bicara Therapeutics price target raised to $39 from $37 at Morgan Stanley

2M ago

Bicara CEO Claire Mazumdar to switch roles, Ryan Cohlhepp to succeed

PremiumThe Fly

Bicara CEO Claire Mazumdar to switch roles, Ryan Cohlhepp to succeed

2M ago

Bicara Therapeutics reports Q2 EPS (82c), consensus (83c)

PremiumThe FlyBicara Therapeutics reports Q2 EPS (82c), consensus (83c)

2M ago

BCAX Earnings this Week: How Will it Perform?

Pre-Earnings

BCAX Earnings this Week: How Will it Perform?

2M ago

Bicara Therapeutics reshapes board for commercialization push

Company Announcements

Bicara Therapeutics reshapes board for commercialization push

2M ago

PremiumRatings

Jeet Mukherjee Reiterates Buy on Bicara, Maintains $28 Price Target on Differentiated Ficera Profile and Upside Potential

2M ago

Bicara Therapeutics Holds 2026 Annual Stockholder Meeting

PremiumCompany Announcements

Bicara Therapeutics Holds 2026 Annual Stockholder Meeting

4M ago

Analyst Reiterates Buy on Bicara, Keeps 12-Month Price Target Unchanged at $42 on Encouraging Ficerafusp Alfa Data

PremiumRatings

Analyst Reiterates Buy on Bicara, Keeps 12-Month Price Target Unchanged at $42 on Encouraging Ficerafusp Alfa Data

4M ago

Bicara Highlights Durable Three-Year Data for Ficerafusp Alfa

PremiumCompany Announcements

Bicara Highlights Durable Three-Year Data for Ficerafusp Alfa

4M ago

Bicara Therapeutics management to meet with Cantor

PremiumThe FlyBicara Therapeutics management to meet with Cantor

4M ago

Bicara Therapeutics Highlights Momentum in Earnings Call

Company Announcements

Bicara Therapeutics Highlights Momentum in Earnings Call

5M ago

Bicara Therapeutics’ Earnings Call Highlights Ficera Momentum

Company Announcements

Bicara Therapeutics’ Earnings Call Highlights Ficera Momentum

5M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >